Folate receptor alpha (FRα) is overexpressed in about 90% of ovarian cancers and is considered to be a good target for both drug design and gene delivery, and some FRα-targeted candidate drugs have already entered clinical trials for ovarian cancer therapy32, 33, 34, 35. Here, FOLR1 is linked to ovarian carcinoma.